Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Cut to "Hold" at BidaskClub
07:40am, Friday, 20'th Mar 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, BidA
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded by ValuEngine to "Buy"
05:54am, Tuesday, 17'th Mar 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Tuesday, ValuEngine reports. Several othe
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) CEO Sanj K. Patel Sells 33,115 Shares of Stock
09:34am, Wednesday, 11'th Mar 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) CEO Sanj K. Patel sold 33,115 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $20.00, for a total tran
Quantitative Systematic Strategies LLC Takes Position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
10:30am, Sunday, 08'th Mar 2020
Quantitative Systematic Strategies LLC purchased a new stake in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) during the fourth quarter, according to the company in its most recent disclosure wi
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Expected to Announce Earnings of -$0.62 Per Share
08:56am, Saturday, 07'th Mar 2020
Brokerages forecast that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will post ($0.62) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Kiniksa Pharm
Kiniksa Pharmaceuticals - Pick Of The Day
09:02pm, Friday, 06'th Mar 2020
Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company.
Kiniksa Pharmaceuticals - Chart Of The Day - Jim Van Meerten
07:33pm, Friday, 06'th Mar 2020
The Barchart Chart of the Day belongs to an under-followed clinical stage biopharmaceutical company Kiniksa Pharmaceuticals (KNSA). I found the sotck by sorting Barchart's Top Stocks to Own list first
California Public Employees Retirement System Invests $111,000 in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
12:20pm, Friday, 06'th Mar 2020
California Public Employees Retirement System bought a new position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) in the 4th quarter, according to the company in its most recent filing with the SEC. Th
Los Angeles Capital Management & Equity Research Inc. Takes Position in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
10:50am, Monday, 02'nd Mar 2020
Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) in the 4th quarter, according to its most recent filing with the Secu
Brokers Issue Forecasts for Kiniksa Pharmaceuticals Ltd's Q1 2020 Earnings (NASDAQ:KNSA)
06:44am, Monday, 02'nd Mar 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) – Stock analysts at Wedbush boosted their Q1 2020 earnings per share estimates for Kiniksa Pharmaceuticals in a note issued to investors on Wednesday, Febru
Cara Therapeutics: Scratching At Multiple Indications In 2020
05:54pm, Friday, 28'th Feb 2020
2020 is a big year for oral Korsuva. CARA took a big hit in late 2019 from oral phase 2 data. The second phase 3 readout for IV Korsuva, KALM-II, is set to repo
BRIEF-Kiniksa Pharmaceuticals Posts Qtrly Loss Per Share Of $0.58
12:44pm, Wednesday, 26'th Feb 2020
Kiniksa Pharmaceuticals Ltd:
Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
12:30pm, Wednesday, 26'th Feb 2020
- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserves of $233 million - HAMILTON, Bermuda, Feb..
Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
12:30pm, Wednesday, 26'th Feb 2020
- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserves of $233 million - ...
John F. Paolini Sells 22,477 Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Stock
10:56am, Sunday, 23'rd Feb 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) SVP John F. Paolini sold 22,477 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $18.
